Press Releases Year All20242023202220212020201920182017201620152014 Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 Dec 18, 2024 Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd. Dec 03, 2024 Coherus Management to Participate in the 2024 Citi Global Healthcare Conference Nov 27, 2024 Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update Nov 06, 2024 Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024 Oct 30, 2024 Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update Aug 08, 2024 Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024 Aug 01, 2024 Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction Jun 27, 2024 Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors Jun 05, 2024 Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference May 30, 2024
Year All20242023202220212020201920182017201620152014 Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 Dec 18, 2024 Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd. Dec 03, 2024 Coherus Management to Participate in the 2024 Citi Global Healthcare Conference Nov 27, 2024 Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update Nov 06, 2024 Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024 Oct 30, 2024 Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update Aug 08, 2024 Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024 Aug 01, 2024 Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction Jun 27, 2024 Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors Jun 05, 2024 Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference May 30, 2024
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 Dec 18, 2024
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd. Dec 03, 2024
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update Nov 06, 2024
Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update Aug 08, 2024
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction Jun 27, 2024
